A Randomized Double-Blind Double-Dummy Active-Controlled Study Comparing the Efficacy Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Recruiting
99 years or below
All
Phase
3
4 participants needed
1 Location
Brief description of study
Please see Section 1 of the attached protocol.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
08 Jul 2020.
Study ID: 842820